Kwality Pharmaceuticals Limited (BOM:539997)
India · Delayed Price · Currency is INR 3,590.75
+146.00 (4.24%)
At close: Aug 17, 2026
Kwality Pharmaceuticals Ratios and Metrics
Market cap in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Total Valuation
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 14, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 37,258 | 13,555 | 9,017 | 4,248 | 3,191 | 6,018 | |
Market Cap Growth | 232.89% | 50.32% | 112.27% | 33.12% | -46.97% | 935.71% |
Enterprise Value | 38,513 | 14,302 | 9,948 | 5,076 | 4,145 | 6,180 |
Last Close Price | 3590.75 | 1306.35 | 869.05 | 409.40 | 307.55 | 580.00 |
Price Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 14, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
PE Ratio | 45.97 | 20.13 | 22.63 | 17.85 | 16.47 | 5.02 |
PS Ratio | 6.73 | 2.69 | 2.44 | 1.38 | 1.27 | 1.32 |
PB Ratio | 11.29 | 4.11 | 3.44 | 1.91 | 1.60 | 3.35 |
P/TBV Ratio | 11.44 | 4.16 | 3.44 | 1.90 | 1.59 | 3.32 |
P/FCF Ratio | - | - | 30.65 | 32.33 | - | 110.54 |
P/OCF Ratio | 224.63 | 81.72 | 17.11 | 9.88 | 7.71 | 9.93 |
EV Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 14, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
EV/Sales Ratio | 6.95 | 2.84 | 2.69 | 1.65 | 1.65 | 1.36 |
EV/EBITDA Ratio | 28.01 | 11.89 | 12.13 | 7.46 | 6.73 | 3.56 |
EV/EBIT Ratio | 32.83 | 14.24 | 15.61 | 10.48 | 8.88 | 3.80 |
EV/FCF Ratio | - | - | 33.81 | 38.62 | - | 113.51 |
Financial Efficiency
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 14, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Debt / Equity Ratio | 0.40 | 0.40 | 0.43 | 0.44 | 0.45 | 0.35 |
Debt / EBITDA Ratio | 0.95 | 1.09 | 1.37 | 1.44 | 1.46 | 0.36 |
Debt / FCF Ratio | - | - | 3.82 | 7.47 | - | 11.61 |
Net Debt / Equity Ratio | 0.39 | 0.39 | 0.37 | 0.41 | 0.42 | 0.28 |
Net Debt / EBITDA Ratio | 0.92 | 1.06 | 1.19 | 1.36 | 1.35 | 0.29 |
Net Debt / FCF Ratio | - | -4.54 | 3.32 | 7.01 | -13.18 | 9.23 |
Asset Turnover | - | 0.97 | 0.88 | 0.82 | 0.72 | 1.80 |
Inventory Turnover | - | 3.29 | 2.33 | 1.92 | 1.63 | 4.88 |
Quick Ratio | - | 1.30 | 1.07 | 0.90 | 0.68 | 0.65 |
Current Ratio | - | 1.80 | 1.67 | 1.60 | 1.65 | 1.63 |
Return on Equity (ROE) | - | 22.74% | 16.41% | 11.20% | 10.18% | 100.10% |
Return on Assets (ROA) | - | 12.08% | 9.47% | 8.10% | 8.40% | 40.13% |
Return on Invested Capital (ROIC) | 19.54% | 18.50% | 13.89% | 12.33% | 13.75% | 75.28% |
Return on Capital Employed (ROCE) | - | 27.40% | 23.00% | 20.00% | 20.50% | 80.90% |
Yields
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 14, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Earnings Yield | 2.18% | 4.97% | 4.42% | 5.60% | 6.07% | 19.94% |
FCF Yield | -0.75% | -2.07% | 3.26% | 3.09% | -1.97% | 0.91% |
Buyback Yield / Dilution | 0.07% | - | - | - | - | -0.00% |
Total Shareholder Return | 0.07% | - | - | - | - | -0.00% |